Acute hyperglycemia and oxidative stress: Direct cause and effect?

Free Radical Biology and Medicine

Volumn 44, Issue 7, 2008, Pages 1217-1231

  Choi, Siu Wai ^a   Benzie, Iris F F ^a   Ma, Shuk Woon ^a   Strain, J J ^b   Hannigan, Bernadette M ^b  

^a HONG KONG POLYTECHNIC UNIVERSITY   (Hong Kong)

^b UNIVERSITY OF ULSTER   (United Kingdom)

Author keywords

Antioxidant; Diabetes; Glucose variability; Glycemic control; Hyperglycemia; Oxidative stress

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALDOSTERONE; AMLODIPINE; ANTIOXIDANT; CANDESARTAN; GLIBENCLAMIDE; GLICLAZIDE; GLIPIZIDE; GLUCOSE; HEMOGLOBIN A1C; INSULIN LISPRO; METFORMIN; PIOGLITAZONE; POLYUNSATURATED FATTY ACID; PRAMLINTIDE; REPAGLINIDE; ROSIGLITAZONE; SPIRONOLACTONE; TRICHLORMETHIAZIDE; TROGLITAZONE; VALSARTAN;

CELL CULTURE; DIABETES MELLITUS; DIABETIC PATIENT; DRUG WITHDRAWAL; GLUCOSE BLOOD LEVEL; GLUCOSE INFUSION; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; LIVER TOXICITY; METABOLIC REGULATION; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW; TREATMENT DURATION;

ANIMALS; ANTIOXIDANTS; CELLS, CULTURED; DIABETES MELLITUS; DIABETES MELLITUS, TYPE 2; GLUCOSE; HUMANS; HYPERGLYCEMIA; MODELS, BIOLOGICAL; OXIDATIVE STRESS; TIME FACTORS;

EID: 40949151200     PISSN: 08915849     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.freeradbiomed.2007.12.005     Document Type: Review

References (88)

1. Diabetes Atlas. http://www.eatlas.idf.org/Costs_of_diabetes/Direct_costs_of_diabetes/.
2. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care, Suppl 1 (2007) S42-S47
3. Evans J.L., Goldfine I.D., Maddux B.A., and Grodsky G.M. Oxidative stress and stress-activated signaling pathways: a unifying hypothesis of type 2 diabetes. Endocr. Rev. 23 (2002) 599-622
4. Scott J.A., and King G.L. Oxidative stress and antioxidant treatment in diabetes. Ann. N. Y. Acad. Sci. 1031 (2004) 204-213
5. West I.C. Radicals and oxidative stress in diabetes. Diabet. Med. 17 (2000) 171-180
6. Rosen P., Nawroth P.P., King G., Moller W., Tritschler H.J., and Packer L. The role of oxidative stress in the onset and progression of diabetes and its complications: a summary of a Congress Series sponsored by UNESCO-MCBN, the American Diabetes Association and the German Diabetes Society. Diabetes/Metab. Res. Rev. 17 (2001) 189-212
7. Jay D., Hitomi H., and Griendling K.K. Oxidative stress and diabetic cardiovascular complications. Free Radic. Biol. Med. 40 (2006) 183-192
8. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 414 (2001) 813-820
9. Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes 54 (2005) 1615-1625
10. Ceriello A., Bortolotti N., Crescentini A., Motz E., Lizzio S., Russo A., Ezsol Z., Tonutti L., and Taboga C. Antioxidant defences are reduced during the oral glucose tolerance test in normal and non-insulin-dependent diabetic subjects. Eur. J. Clin. Invest. 28 (1998) 329-333
11. Ma S.W., Tomlinson B., and Benzie I.F. A study of the effect of oral glucose loading on plasma oxidant:antioxidant balance in normal subjects. Eur. J. Nutr. 44 (2005) 250-254
12. Monnier L., Lapinski H., and Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). Diabetes Care 26 (2003) 881-885
13. Sampson M.J., Gopaul N., Davies I.R., Hughes D.A., and Carrier M.J. Plasma F2 isoprostanes: direct evidence of increased free radical damage during acute hyperglycemia in type 2 diabetes. Diabetes Care 25 (2002) 537-541
14. Milne G.L., Sanchez S.C., Musiek E.S., and Morrow J.D. Quantification of F2-isoprostanes as a biomarker of oxidative stress. Nat. Protoc. 2 (2007) 221-226
15. Njalsson R., and Norgren S. Physiological and pathological aspects of GSH metabolism. Acta Paediatr. 94 (2005) 132-137
16. Lee C.Y., Jenner A.M., and Halliwell B. Rapid preparation of human urine and plasma samples for analysis of F2-isoprostanes by gas chromatography-mass spectrometry. Biochem. Biophys. Res. Commun. 320 (2004) 696-702
17. Miyazaki Y., Kawano H., Yoshida T., Miyamoto S., Hokamaki J., Nagayoshi Y., Yamabe H., Nakamura H., Yodoi J., and Ogawa H. Pancreatic B-cell function is altered by oxidative stress induced by acute hyperglycaemia. Diabet. Med. 24 (2007) 154-160
18. Burke-Gaffney A., Callister M.E., and Nakamura H. Thioredoxin: friend or foe in human disease?. Trends Pharmacol. Sci. 26 (2005) 398-404
19. Moller L., Hofer T., and Zeisig M. Methodological considerations and factors affecting 8-hydroxy-2-deoxyguanosine analysis. Free Radic. Res. 29 (1998) 511-524
20. Tessier D., Khalil A., and Fulop T. Effects of an oral glucose challenge on free radicals/antioxidants balance in an older population with type II diabetes. J. Gerontol. A Biol. Sci. Med. Sci. 54 (1999) M541-M545
21. Rumsey S.C., Kwon O., Xu G.W., Burant C.F., Simpson I., and Levine M. Glucose transporter isoforms GLUT1 and GLUT3 transport dehydroascorbic acid. J. Biol. Chem. 272 (1997) 18982-18989
22. Levine M., Conry-Cantilena C., Wang Y., Welch R.W., Washko P.W., Dhariwal K.R., Park J.B., Lazarev A., Graumlich J.F., King J., and Cantilena L.R. Vitamin C pharmacokinetics in healthy volunteers: evidence for a recommended dietary allowance. Proc. Natl. Acad. Sci. U. S. A. 93 (1996) 3704-3709
23. Padayatty S.J., and Levine M. New insights into the physiology and pharmacology of vitamin C. CMAJ 64 (2001) 353-355
24. Costa A., Iguala I., Bedini J., Quinto L., and Conget I. Uric acid concentration in subjects at risk of type 2 diabetes mellitus: relationship to components of the metabolic syndrome. Metabolism 51 (2002) 372-375
25. Benzie I.F. Lipid peroxidation: a review of causes, consequences, measurement and dietary influences. Int. J. Food Sci. Nutr. 47 (1996) 233-261
26. Yano M., Hasegawa G., Ishii M., Yamasaki M., Fukui M., Nakamura N., and Yoshikawa T. Short-term exposure of high glucose concentration induces generation of reactive oxygen species in endothelial cells: implication for the oxidative stress associated with postprandial hyperglycemia. Redox Rep. 9 (2004) 111-116
27. Ha H., and Lee H.B. Reactive oxygen species as glucose signaling molecules in mesangial cells cultured under high glucose. Kidney Inter., Suppl. 77 (2000) S19-S25
28. Graier W.F., Posch K., Fleischhacker E., Wascher T.C., and Kostner G.M. Increased superoxide anion formation in endothelial cells during hyperglycemia: an adaptive response or initial step of vascular dysfunction?. Diabetes Res. Clin. Pract. 45 (1999) 153-160
29. DeFronzo R.A., Tobin J.D., and Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am. J. Physiol. 237 (1979) E214-E223
30. Marfella R., Quagliaro L., Nappo F., Ceriello A., and Giugliano D. Acute hyperglycemia induces an oxidative stress in healthy subjects. J. Clin. Invest. 108 (2001) 635-636
31. Ryberg H., and Caidahl K. Chromatographic and mass spectrometric methods for quantitative determination of 3-nitrotyrosine in biological samples and their application to human samples. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 851 (2007) 160-171
32. Halliwell B., and Gutteridge J. Free Radicals in Biology and Medicine. Fourth Edition (2007), Oxford University Press, Oxford
33. Shishehbor M.H., Aviles R.J., Brennan M.L., Fu X., Goormastic M., Pearce G.L., Gokce N., Keaney Jr. J.F., Penn M.S., Sprecher D.L., Vita J.A., and Hazen S.L. Association of nitrotyrosine levels with cardiovascular disease and modulation by statin therapy. JAMA 289 (2003) 1675-1680
34. Koya D., and King G.L. Protein kinase C activation and the development of diabetic complications. Diabetes 47 (1998) 859-866
35. Ceriello A., Assaloni R., Da Ros R., Maier A., Piconi L., Quagliaro L., Esposito K., and Giugliano D. Effect of atorvastatin and irbesartan, alone and in combination, on postprandial endothelial dysfunction, oxidative stress, and inflammation in type 2 diabetic patients. Circulation 17 (2005) 2518-2524
36. Baillie G.M., Sherer J.T., and Weart C.W. Insulin and coronary artery disease: is syndrome X the unifying hypothesis?. Ann. Pharmacother. 32 (1998) 233-247
37. Kyselova P., Zourek M., Rusavy Z., Trefil L., and Racek J. Hyperinsulinemia and oxidative stress. Physiol. Res. 51 (2002) 591-595
38. Bravi M.C., Armiento A., Laurenti O., Cassone-Faldetta M., De Luca O., Moretti A., and De Mattia G. Insulin decreases intracellular oxidative stress in patients with type 2 diabetes mellitus. Metabolism 55 (2006) 691-695
39. Janero D.R. Malondialdehyde and thiobarbituric acid-reactivity as diagnostic indices of lipid peroxidation and peroxidative tissue injury. Free Radic. Biol. Med. 9 (1990) 515-540
40. Esterbauer H. Estimation of peroxidative damage. A critical review. Pathol. Biol. (Paris) 44 (1996) 25-28
41. Galvan A.Q., Muscelli E., Catalano C., Natali A., Sanna G., Masoni A., Bernardini B., Barsacchi R., and Ferrannini E. Insulin decreases circulating vitamin E levels in humans. Metabolism 45 (1996) 998-1003
42. Quinones-Galvan A., Sironi A.M., Baldi S., Galetta F., Garbin U., Fratta-Pasini A., Cominacini L., and Ferrannini E. Evidence that acute insulin administration enhances LDL cholesterol susceptibility to oxidation in healthy humans. Arterioscler. Thromb. Vasc. Biol. 19 (1999) 2928-2932
43. McNulty P.H., Robertson B.J., Tulli M.A., Lendel V., Harach L.A., Scott S., and Boehmer J.P. Effect of Post-prandial Hyperglycemia on Endothelium-dependent and -Independent Coronary Blood FLow in Human Subjects. Am. J. Physiol. Heart Circ. Physiol. 293 (2007) 103-108
44. Rask-Madsen C., and King G.L. Mechanisms of Disease: endothelial dysfunction in insulin resistance and diabetes. Nat. Clin. Pract. Endocrinol. Metab. 3 (2007) 46-56
45. Ceriello A., Kumar S., Piconi L., Esposito K., and Giugliano D. Simultaneous control of hyperglycemia and oxidative stress normalizes endothelial function in type 1 diabetes. Diabetes Care 30 (2007) 649-654
46. Monnier L., Mas E., Ginet C., Michel F., Villon L., Cristol J.P., and Colette C. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA 295 (2006) 1681-1687
47. Quagliaro L., Piconi L., Assaloni R., Martinelli L., Motz E., and Ceriello A. Intermittent high glucose enhances apoptosis related to oxidative stress in human umbilical vein endothelial cells: the role of protein kinase C and NAD(P)H-oxidase activation. Diabetes 52 (2003) 2795-2804
48. Okouchi M., Okayama N., and Aw T.Y. Hyperglycemia potentiates carbonyl stress-induced apoptosis in naive PC-12 cells: relationship to cellular redox and activator protease factor-1 expression. Curr. Neurovasc. Res. 2 (2005) 375-386
49. Kilpatrick E.S., Rigby A.S., and Atkin S.L. The effect of glucose variability on the risk of microvascular complications in type 1 diabetes. Diabetes Care 29 (2006) 1486-1490
50. The DCCT Research Group. The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the diabetes control and complications trial. Diabetes 44 (1995) 968-983
51. Kilpatrick E.S., Rigby A.S., and Atkin S.L. Variability in the relationship between mean plasma glucose and HbA1c: implications for the assessment of glycemic control. Clin. Chem. 53 (2007) 897-901
52. Kilpatrick E.S., Rigby A.S., and Atkin S.L. The effect of glucose variability on the risk of microvascular complications in type 1 diabetes. Diabetes Care 30 (2007) 187-188
53. Giannini S., Serio M., and Galli A. Pleiotropic effects of thiazolidinediones: taking a look beyond antidiabetic activity. J. Endocrinol. Invest. 27 (2004) 982-991
54. Watanabe T., Yasunari K., and Nakamura M. Antioxidative actions of statins: potential mechanisms for antiathersclerotic effects. Mini Rev. Med. Chem. 6 (2006) 505-508
55. Benzie I.F., and Tomlinson B. Antioxidant power of angiotensin-converting enzyme inhibitors in vitro. Br. J. Clin. Pharmacol. 45 (1998) 168-169
56. Bonnefont-Rousselot D., Raji B., Walrand S., Gardes-Albert M., Jore D., Legrand A., Peynet J., and Vasson M.P. An intracellular modulation of free radical production could contribute to the beneficial effects of metformin towards oxidative stress. Metabolism 52 (2003) 586-589
57. Rahbar S., Natarajan R., Yerneni K., Scott S., Gonzales N., and Nadler J.L. Evidence that pioglitazone, metformin and pentoxifylline are inhibitors of glycation. Clin. Chim. Acta 301 1-2 (2000) 65-77
58. Inoue I., Katayama S., Takahashi K., Negishi K., Miyazaki T., Sonoda M., and Komoda T. Troglitazone has a scavenging effect on reactive oxygen species. Biochem. Biophys. Res. Commun. 235 (1997) 113-116
59. Škrha J. Diabetes and vascular disease: From pathogenesis to treatment. Are vascular effects of hypoglycemic and hypolipidemic drugs independent of their metabolic effects?. Diabetes and Metab. Syndr.: Clin. Res. Rev. 1 (2007) 61-69
60. Pavlovic D., Kocic R., Kocic G., Jevtovic T., Radenkovic S., Mikic D., Stojanovic M., and Djordjevic P.B. Effect of four-week metformin treatment on plasma and erythrocyte antioxidative defense enzymes in newly diagnosed obese patients with type 2 diabetes. Diabetes Obes. Metab. 2 (2000) 251-256
61. Tankova T., Koev D., Dakovska L., and Kirilov G. The effect of repaglinide on insulin secretion and oxidative stress in type 2 diabetic patients. Diabetes Res. Clin. Pract. 59 (2003) 43-49
62. Ceriello A., Lush C.W., Darsow T., Piconi L., Corgnali M., Nanayakkara N., Frias J.P., and Maggs D. Pramlintide reduced markers of oxidative stress in the postprandial period in patients with type 2 diabetes. Diabetes Metab. Res. Rev. 24 (2008) 103-108. http://www.interscience.wiley.com/cgi-bin/fulltext/114802795/HTMLSTART Accessed on http://www.interscience.wiley.com/cgi-bin/fulltext/114802795/HTMLSTART.
63. Ghiselli A., Serafini M., Maiani G., Azzini E., and Ferro-Luzzi A. A fluorescence-based method for measuring total plasma antioxidant capability. Free Radic. Biol. Med. 18 (1995) 29-36
64. Agarwal R. Anti-inflammatory effects of short-term pioglitazone therapy in men with advanced diabetic nephropathy. Am. J. Physiol. Renal. Physiol. 290 (2006) F600-F605
65. O'Brien R.C., Luo M., Balazs N., and Mercuri J. In vitro and in vivo antioxidant properties of gliclazide. J. Diabetes Complications 14 (2000) 201-206
66. Halliwell B., Hoult J.R., and Blake D.R. Oxidants, inflammation, and anti-inflammatory drugs. FASEB J. 2 (1988) 2867-2873
67. Scott N.A., Jennings P.E., Brown J., and Belch J.J. Gliclazide: a general free radical scavenger. Eur. J. Pharmacol. 208 (1991) 175-177
68. Jennings P.E., and Belch J.J. Free radical scavenging activity of sulfonylureas: a clinical assessment of the effect of gliclazide. Metabolism 49 (2000) 23-26
69. Gumieniczek A. Oxidative stress in kidney and liver of alloxan-induced diabetic rabbits: effect of repaglinide. Acta Diabetol. 42 (2005) 75-81
70. Gumieniczek A. Effect of the new thiazolidinedione-pioglitazone on the development of oxidative stress in liver and kidney of diabetic rabbits. Life Sci. 74 (2003) 553-562
71. Miller N.J., Rice-Evans C., Davies M.J., Gopinathan V., and Milner A. A novel method for measuring antioxidant capacity and its application to monitoring the antioxidant status in premature neonates. Clin. Sci. (Lond). 84 (1993) 407-412
72. Dobrian A.D., Schriver S.D., Khraibi A.A., and Prewitt R.L. Pioglitazone prevents hypertension and reduces oxidative stress in diet-induced obesity. Hypertension 43 (2004) 48-56
73. Ogawa S., Mori T., Nako K., Kato T., Takeuchi K., and Ito S. Angiotensin II type 1 receptor blockers reduce urinary oxidative stress markers in hypertensive diabetic nephropathy. Hypertension 47 (2006) 699-705
74. Takebayashi K., Matsumoto S., Aso Y., and Inukai T. Aldosterone blockade attenuates urinary monocyte chemoattractant protein-1 and oxidative stress in patients with type 2 diabetes complicated by diabetic nephropathy. J. Clin. Endocrinol. Metab. 91 (2006) 2214-2217
75. Franzoni F., Quinones-Galvan A., Regoli F., Ferrannini E., and Galetta F. A comparative study of the in vitro antioxidant activity of statins. Int. J. Cardiol. 90 (2003) 317-321
76. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352 (1998) 837-853
77. Hunt J.V. Ascorbic acid and diabetes mellitus. Subcell Biochem. 25 (1996) 369-405
78. Choi S.W., Benzie I.F., Lam C.S., Chat S.W., Lam J., Yiu C.H., Kwan J.J., Tang Y.H., Yeung G.S., Yeung V.T., Woo G.C., Hannigan B.M., and Strain J.J. Inter-relationships between DNA damage, ascorbic acid and glycaemic control in Type 2 diabetes mellitus. Diabet. Med. 22 (2005) 1347-1353
79. Khaw K.T., Bingham S., Welch A., Luben R., Wareham N., Oakes S., and Day N. Relation between plasma ascorbic acid and mortality in men and women in EPIC-Norfolk prospective study: a prospective population study. European Prospective Investigation into Cancer and Nutrition. Lancet 357 (2001) 657-663
80. Boekholdt S.M., Meuwese M.C., Day N.E., Luben R., Welch A., Wareham N.J., and Khaw K.T. Plasma concentrations of ascorbic acid and C-reactive protein, and risk of future coronary artery disease, in apparently healthy men and women: the EPIC-Norfolk prospective population study. Br. J. Nutr. 96 (2006) 516-522
81. Cadenas E., and Packer L. Antioxidants in health and disease. In: Packer L., and Fuchs J. (Eds). Vol. 3 of Handbook of antioxidants (1996), Marcel Dekker, New York
82. Benzie I.F., and Strain J.J. Ferric reducing/antioxidant power assay: direct measure of total antioxidant activity of biological fluids and modified version for simultaneous measurement of total antioxidant power and ascorbic acid concentration. Methods Enzymol. 299 (1999) 15-27
83. Comparison of different methods of measuring 8-oxoguanine as a marker of oxidative DNA damage. ESCODD (European Standards Committee on Oxidative DNA Damage). Free Radic. Res. 32 (2000) 333-341
84. Benzie I.F., Chung W., and Tomlinson B. Simultaneous measurement of allantoin and urate in plasma: analytical evaluation and potential clinical application in oxidant:antioxidant balance studies. Clin. Chem. 45 (1999) 901-904
85. Morrow J.D. Quantification of isoprostanes as indices of oxidant stress and the risk of atherosclerosis in humans. Arterioscler. Thromb. Vasc. Biol. 25 (2005) 279-286
86. Helmersson J., and Basu S. Intra-day variation of in vivo prostaglandin F2alpha formation in healthy subjects. Prostaglandins Other Lipid Mediat. 80 (2006) 93-99
87. Uchida K. 4-Hydroxy-2-nonenal: a product and mediator of oxidative stress. Prog. Lipid Res. 42 (2003) 318-343
88. Hirsch I.B., and Brownlee M. Should minimal blood glucose variability become the gold standard of glycemic control?. J. Diabetes Complications. 19 (2005) 178-181